Adaptive Biotechnologies (ADPT) Current Assets (2018 - 2026)

Adaptive Biotechnologies has reported Current Assets for 9 years, with the latest figure at $291.8 million in Q1 2026.

• Quarterly Current Assets rose 13.77% year-over-year to $291.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $291.8 million (up 13.77% YoY) and the FY2025 annual result came in at $300.2 million, up 5.79% from the prior year.
• Current Assets slipped to $291.8 million in Q1 2026 per ADPT's latest filing, from $300.2 million in the prior quarter.
• Over five years, Current Assets peaked at $564.4 million in Q3 2022 and troughed at $256.5 million in Q1 2025.
• A 5-year average of $383.4 million and a median of $374.0 million in 2024 frame the typical range for Current Assets.
• The widest YoY moves for Current Assets: up 39.58% in 2022, down 45.21% in 2022.
• Over 5 years, Current Assets stood at $562.1 million in 2022, then retreated by 27.03% to $410.2 million in 2023, then slumped by 30.82% to $283.8 million in 2024, then increased by 5.79% to $300.2 million in 2025, then retreated by 2.79% to $291.8 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $291.8 million, $300.2 million, and $281.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.